Named after the hundred-eyed watchman of Greek myth, Argus watches the education landscape: spotting new opportunities, pressure-testing the ventures we're building, and tracing every read back to the real-world signals behind it.
The evidence library: the raw signals the pipeline is watching across the education ecosystem. Every idea is built from these.
The Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is inviting public comments on the proposed revisions to an information collection. The Monitoring and Compliance for ORR Care Provider Facilities information collection consists of several forms that will allow the Monitoring and Compliance Bureau (MCB) and Unaccompanied Alien Children Bureau (UACB) to better monitor UACB- funded care provider facilities for compliance with federal and state laws and regulations, licensing and accreditation standards, ORR policies and procedures, and child welfare standards. This request includes the addition of nine new instruments, discontinuation of obsolete instruments, and revisions to remaining currently approved instruments.
The Office of Refugee Resettlement (ORR) is requesting a 3- year extension with revisions of the Unaccompanied Refugee Minors (URM) Program ORR-3 Report and ORR-4 Report (Office of Management and Budget #: 0970-0034, expiration November 30, 2026). Revisions were made to reduce burden and streamline information collection.
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
The Administration for Children and Families (ACF) Office of Refugee Resettlement (ORR) is requesting to move the Serious Medical Procedure Request (SMR) Form (Office of Management and Budget (OMB) #: 0970-0561, expiration date December 31, 2026) under the Medical Assessment Form and Dental Assessment Form (OMB #: 0970-0466, expiration October 31, 2026) information collection and update the title of OMB # 0970-0466 to Office of Refugee Resettlement (ORR) Unaccompanied Alien Child Health Forms. Revisions are proposed to the forms. The proposed restructuring and revisions will improve transparency, lessen burden, improve data quality, and ensure alignment with ORR requirements. In addition, to ensure continuity of care, the request has been revised to include the sharing of health information with the Department of Homeland Security (DHS) in specific circumstances.
The Administration for Children and Families (ACF) proposes to extend data collection under the existing overarching generic clearance for Formative Data Collections for ACF Research and Evaluation (Office of Management and Budget (OMB)#: 0970-0356). There are no changes proposed to the intended purpose or use of the potential data collections, but burden has been adjusted to reflect agency priorities.
In accordance with the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS) is providing notice of the re-establishment of a matching program between CMS and the Department of War for "Verification of Eligibility for Minimum Essential Coverage Under the Patient Protection and Affordable Care Act through a Department of War Health Benefits Plan."
The Center for Drug Evaluation and Research (CDER) within the Food and Drug Administration (FDA or Agency), through its Quantitative Medicine Center of Excellence (QM CoE), is announcing a request for information to inform the development of a Quantitative Medicine Innovation Network (QMIN). The vision for the QMIN is to create a cross-sector collaborative platform that accelerates the translation of quantitative medicine approaches to transform drug development, regulatory science, and clinical decision-making for patient benefit. The purpose of this request is to obtain feedback from industry, academia, healthcare providers, patient groups, and other interested parties on identifying critical community needs and establishing mechanisms for continuous engagement, supporting collaborative demonstration projects or research on innovative approaches aimed at addressing high priority areas through the application of QM approaches, and exploring mechanisms to leverage community expertise a
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces nine separate awards to fund Institut National Hygiene Publique, Cote d'Ivoire; Ministry of Health-Centers for Disease Control and Prevention, Egypt; Ethiopian Public Health Institute; Noguchi Memorial Institute for Medical Research, Ghana; Institut National d Hygiene, Morocco; Institut Pasteur de Dakar, Senegal; Institut Pasteur de Tunis, Tunisia; Uganda Virus Research Institute; University Teaching Hospital, Zambia. For Institut National Hygiene Publique, Cote d'Ivoire, the award is for approximately $800,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For Ministry of Health-Centers for Disease Control and Prevention, Egypt, the award is for approximately $800,000 in FFY 2026, subject to the availability of funds. For Ethiopian Public Health Institute, the award is for approximately $800,000 in FFY 2026, subject to the availabi
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces five separate awards to fund HEADA Cameroon; Instituto Nacional de Saude, Mozambique; Nigeria Centre for Disease Control and Prevention; National Institute of Health, Pakistan; Kinshasa School of Public Health, Democratic Republic of the Congo. For Association HEADA Cameroon, the award is for approximately $600,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For Instituto Nacional de Saude, Mozambique, the award is for approximately $900,000 in FFY 2026, subject to the availability of funds. For Nigeria Centre for Disease Control and Prevention, the award is for approximately $800,000 in FFY 2026, subject to the availability of funds. For National Institute of Health, Pakistan, the award is for approximately $800,000 in FFY 2026, subject to the availability of funds. For Kinshasa School of Public Health, Democratic Republic of th
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces six separate awards to fund the Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran, Argentina; Instituto de Salud Publica de Chile, Chile; Ministerio de Salud P[uacute]blica de Ecuador, Ecuador; Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama; Alter Vida Centro De Estudios Y Formaci[oacute]n Para Ecodesarrollo, Paraguay; Caribbean Public Health Agency, Caribbean Region. For Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran, Argentina, the award is for approximately $600,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For Instituto de Salud Publica de Chile, Chile, the award is for approximately $600,000 in FFY 2026, subject to the availability of funds. For Ministerio de Salud P[uacute]blica de Ecuador, Ecuador, the award is for approximately $800,0
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces four separate awards to fund the Ministry of Health, Bhutan; National Influenza Center, Mongolia; Research Institute for Tropical Medicine, Philippines; Bangkok Metropolitan Administration, Thailand. For Ministry of Health, Bhutan, the award is for approximately $800,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For National Influenza Center, Mongolia, the award is for approximately $600,000 in FFY 2026, subject to the availability of funds. For Research Institute for Tropical Medicine, Philippines, the award is for approximately $600,000 in FFY 2026, subject to the availability of funds. For Bangkok Metropolitan Administration, Thailand, the award is for approximately $900,000 in FFY 2026, subject to the availability of funds. The total FFY 2026 funding amount for the four recipients is $2,900,000. Funding amounts for years 2-
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund the Universidad Peruana Cayetano Heredia for approximately $600,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund The Task Force for Global Health for approximately $4,000,000, in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund HJF Medical Research International, Inc., Kenya, for approximately $1,000,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund Fondacioni SECID, Balkan Region, for approximately $800,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund Fundacion Mexico-Estados Unidos Para La Ciencia, A.C. for approximately $800,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Food and Drug Administration (FDA or we) received objections and requests for a public hearing submitted by Buchanan Ingersoll & Rooney PC, on behalf of Micro-Tracers, Inc. (Micro-Tracers or objector), on the order granting a color additive petition (3C0323) requesting that we repeal specified regulations to no longer provide for the safe use of FD&C Red No. 3 in food (including dietary supplements) and ingested drugs. After reviewing the objections, we have concluded that the objections do not raise issues of material fact that justify a hearing. We are also providing notice that the administrative stay of the effective date for the repeal and delisting of the color additive regulations is now lifted.
This meeting notice announces the virtual meeting public components of the Healthcare Advisory Committee (HAC or Committee) for the fiscal year 2026-2027. The purpose of the Committee is to advise the Secretary of HHS and the CMS Administrator on programs and policies that can improve the United States healthcare system consistent with the Executive Order Establishing the President's Make American Healthy Again Commission. The virtual meetings are open to the public.
This final rule will revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; make changes relating to Medicare graduate medical education (GME) for teaching hospitals; update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); update and make changes to requirements for certain quality programs; and make other policy- related changes. ONC also adopts certain health information technology (health IT) standards and specifications on behalf of HHS.
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry titled "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs." This revised draft guidance provides recommendations for the design and conduct of studies to evaluate the in vivo skin irritation (and sensitization, if applicable) potential of a proposed transdermal or topical delivery system (collectively referred to as TDS). The recommendations in this revised draft guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The revised draft guidance is intended to clarify FDA's recommendations and expectations related to in vivo skin irritation and in vivo combined skin irritation and sensitization studies. This draft guidance replaces the draft guidance "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs" (April 2023).
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs." This guidance provides recommendations for the design and conduct of studies evaluating the adhesion performance of a transdermal or topical delivery system (collectively referred to as TDS). Depending on the objectives of a generic TDS product development program, applicants may choose to evaluate TDS adhesion in studies performed to evaluate TDS adhesion only, or in studies performed with a combined purpose (e.g., for the simultaneous evaluation of adhesion and bioequivalence (BE) with pharmacokinetic (PK) endpoints). The recommendations in this guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The guidance replaces the draft guidance (Revision 2) "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs," issued on April 13, 2
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts." This draft guidance is intended to help applicants develop container closure systems and device constituent parts for proposed biosimilar and interchangeable biosimilar products. This draft guidance expands on and clarifies the Agency's recommendations and expectations regarding the development of delivery devices and container closure systems described in Q.I.4 of the guidance for industry entitled "Questions and Answers on Biosimilar Development and the BPCI Act" and the guidance for industry entitled "Considerations in Demonstrating Interchangeability With a Reference Product" for biosimilar and interchangeable biosimilar products, respectively.
The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \1\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternati
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Angela Anatilde Baquero from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Angela Anatilde Baquero was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Mrs. Baquero was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of May 6, 2026 (30 days after receipt of the notice), Mrs. Baquero has not responded. Mrs. Baquero's failure to respond and request a hearing constitutes a waiver of Mrs. Baquero's right to a hearing concerning this matter.
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Ricardo Andres Acuna from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Ricardo Andres Acuna was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Mr. Acuna was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of May 6, 2026 (30 days after receipt of the notice), Mr. Acuna has not responded. Mr. Acuna's failure to respond and request a hearing constitutes a waiver of Mr. Acuna's right to a hearing concerning this matter.
The Department of Health and Human Services (HHS) provides notice of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines) using Urine and the laboratories currently certified to meet the standards of the Mandatory Guidelines using Oral Fluid.
This final rule updates the prospective payment rates for inpatient rehabilitation facilities (IRFs) for Federal fiscal year (FY) 2027. As required by statute, this final rule includes the classification and weighting factors for the IRF prospective payment system's (PPS) case-mix groups and a description of the methodologies and data used in computing the prospective payment rates for FY 2027. It also finalizes the third and final of the 3-year phaseout of the rural adjustment, which began in FY 2025. This final rule includes a solicitation for public comments on alternative data sources for the IRF PPS wage index; requires all therapy treatments and/or therapy evaluations to begin no later than 36 hours from midnight on the day of admission; finalizes requirements for the initial Interdisciplinary Team meeting to occur on or before 4 days from the date the patient is admitted; and summarizes a request for information on potential future IRF PPS payment reform. Additionally, this fina
The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the proposed rule that appeared in the Federal Register of May 6, 2026, to modify certain terminology in Title 21 of the Code of Federal Regulations (CFR) to comply with Executive Order (E.O.) 14168, "Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government," issued on January 20, 2025. Specifically, this proposed rule, if finalized, will remove the term "gender" wherever it appears and either replace it with the term "sex," or delete reference to gender, as applicable, along with other editorial changes to improve readability. The Agency is taking this action to allow interested persons additional time to submit comments.
This final rule removes duplicative and unnecessary sections from the Family Violence Prevention and Services Program regulations. These amendments will streamline the Family Violence Prevention and Services regulations and make them more accessible to the public.
This final rule updates the hospice wage index, payment rates, and aggregate cap amount for fiscal year 2027. This final rule also includes an analysis of Medicare non-hospice spending, including details regarding a hospice service and spending variation index, and finalizes the requirement that hospices provide the hospice election statement addendum to all Medicare beneficiaries at the time of hospice election. Additionally, this rule finalizes conforming changes to discharge from hospice care regulations and changes to the face-to-face encounter regulations. This final rule also includes a summary of comments received on our requests for information regarding community- based palliative care; the construction of a hospice specific wage index; and the overlap between hospice and medical aid in dying laws. Finally, this rule finalizes changes to the Hospice Quality Reporting Program.
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information
This final rule finalizes changes and updates to the policies and payment rates used under the Skilled Nursing Facility (SNF) Prospective Payment System (PPS) for fiscal year (FY) 2027. This final rule also updates the requirements for the SNF Quality Reporting Program and the SNF Value-Based Purchasing Program.
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
This final rule amends the Grants to States for Public Assistance Programs regulations, the General Administration--State Plans and Grant Appeals regulations, the General Administration--Public Assistance Programs regulations, the Training and Use of Subprofessionals and Volunteers regulations, the Coverage and Conditions of Eligibility in Financial Assistance Programs regulations, the Financial Assistance to Individuals regulations, the Administration of Financial Assistance Programs regulations, the Fiscal Administration of Financial Assistance Programs regulations, the General Temporary Assistance for Needy Families (TANF) Provisions regulations, the Ensuring That Recipients Work regulations, the Accountability Provisions--General regulations, the Expenditures of State and Federal TANF Funds regulations, the Other Accountability Provisions regulations, the Data Collection and Reporting Requirements regulations, the High Performance Bonus Awards regulations, the Implementation of Sec
This final rule updates the prospective payment rates, the outlier threshold, and the wage index for Medicare inpatient hospital services provided by Inpatient Psychiatric Facilities (IPFs), which include psychiatric hospitals and excluded psychiatric units of an acute care hospital or critical access hospital. This final rule also refines the Inpatient Psychiatric Facilities Prospective Payment System (IPF PPS) outlier policy. These changes will be effective for IPF discharges occurring during the fiscal year beginning October 1, 2026, through September 30, 2027. We are also finalizing the implementation of a standardized IPF patient assessment instrument, and removing two measures used in the Inpatient Psychiatric Facilities Quality Reporting Program.
The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&M) Committee. This meeting is open to the public, limited only by the number of audio lines available. Online registration is required.
This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the extension with change of the currently approved information collection "AHRQ Consumer Assessment of Healthcare Providers and Systems (CAHPS) Database for Health Plans" (OMB Control number 0935-0165, last approved on December 31, 2023).
This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the extension without change of the information collection project "Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery" (0935-0179).